Aortic stenosis is a significant and devastating disease that progresses through both the valve and the myocardium.

Image Genetic Dilated Cardiomyopathy

Aortic stenosis is a progressive disease characterized by fibro-calcification of the aortic valve and cardiac damage, reducing blood flow from the heart. Aortic stenosis is the third most common cardiovascular condition in the U.S. and is known to lead to heart failure and death without intervention.

With no approved therapy to treat the cause of this progressive disease, people with aortic stenosis are left to “watchful waiting” as the current standard of care until the condition advances to the severe stage which requires surgery. There is a critical unmet need for new therapies to treat the underlying cause of the disease and mitigate the need for valve replacement surgery, a challenge compounded by limited understanding of the biology driving valvular calcification and disease progression.

Heart background

Ataciguat for Aortic Stenosis

Ataciguat is an investigational soluble guanylate cyclase (sGC) activator that has the potential to restore sGC function to reduce calcium deposition and improve cardiac function.

  • In aortic stenosis, oxidative stress impairs sGC function, disrupting protective nitric oxide (NO)–cGMP signaling. This activates valvular interstitial cells (VICs) that drive osteogenic signaling, valvular remodeling, and downstream calcification
  • Ataciguat is an investigational oral small molecule that may selectively bind to and reactivate the oxidized form of sGC within VICs
  • Reactivation of oxidized sGC and restoration of the NO-cGMP pathway may reduce osteogenic signaling, slowing calcium deposition and potentially delaying disease progression and preserving cardiopulmonary function

This is an investigational compound under clinical study. Safety and efficacy have not been proven yet.

Kardigan is developing ataciguat, a once-daily, oral soluble guanylate cyclase activator, as a potential first-in-class treatment for people with mild to moderate aortic stenosis. Current standard of care for the treatment of aortic stenosis is ‘watchful waiting’ until the disease progresses to the advanced stage which requires valve replacement surgery. Ataciguat has the potential to revolutionize the management of aortic stenosis as the first therapeutic to treat the underlying cause of the disease.

In a 6-month, Phase 2 clinical trial, treatment with ataciguat demonstrated over a 50% reduction in aortic valve calcium versus placebo, improved ventricular structure and function, and no observed effects on blood pressure, results that were consistent with preclinical evidence.

The Phase 2b KATALYST-AV clinical trial has completed enrollment and will evaluate the effect of ataciguat on slowing the progression of aortic valve calcium and cardiopulmonary function.

Learn more about the KATALYST-AV clinical trial.

Kardigan acquired rights to ataciguat, an investigational drug developed by, and in-licensed from, Sanofi and Mayo Clinic.